- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- EQS-NVR: MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
More ▼
Key statistics
On Friday, MorphoSys AG (MOR2:DUS) closed at 16.70, -1.76% below its 52-week high of 17.00, set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.50 |
---|---|
High | 16.80 |
Low | 16.50 |
Bid | 16.70 |
Offer | 17.00 |
Previous close | 16.80 |
Average volume | 124.00 |
---|---|
Shares outstanding | 150.87m |
Free float | 145.30m |
P/E (TTM) | -- |
Market cap | 2.75bn USD |
EPS (TTM) | -1.49 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:31 BST.
More ▼